PROCEPT BioRobotics Corporation (PRCT)
NASDAQ: PRCTHealth CareMedical/Dental InstrumentsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
PRCT stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.42B
- EPS (TTM)
- -$2.02
- Dividend yield
- None
- 52-week range
- 16.67 – 38.11
- Day range
- 24.64 – 26.52
- Volume / Avg
- 1.04M / 1.31M
- Beta
- —
- Shares outstanding
- 57.54M
52-week range
PRCT stock today
On Nov 20, PRCT ended the session at $24.70, shedding $1.05 (4.08%), versus the S&P 500's 3.70% decline. Shares are 35.2% below their 52-week high of $38.11, set on Dec 5, 2025 and 48.2% above the 52-week low of $16.67, in the middle of the past year's range. PRCT is down 21.5% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 17.3%.
PROCEPT BioRobotics has posted a net loss over the last twelve months (EPS of -$2.02), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About PROCEPT BioRobotics
Company profilePROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- CEO
- Mr. Larry L. Wood
- Headquarters
- San Jose, CA
- Employees
- 888
- IPO year
- 2021
- Website
- procept-biorobotics.com
Financial highlights
Full financialsIn fiscal 2025, PROCEPT BioRobotics generated $308.1 million in revenue, up 37.2% from fiscal 2024, its 5th consecutive year of revenue growth. PROCEPT BioRobotics reported a net loss of $95.6 million, compared with a loss of $91.4 million a year earlier. Gross margin was 63.7% (up from 61.1%) and operating margin -33.7%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $308.05M | $224.50M | $136.19M | $75.01M | $34.47M |
| Growth | +37.22% | +64.84% | +81.55% | +117.60% | +346.72% |
| Net income | $-95.57M | $-91.41M | $-105.90M | $-87.15M | $-59.85M |
| EPS (diluted) | $-1.72 | $-1.75 | $-2.24 | $-1.96 | $-3.63 |
Analyst forecast
ForecastConsensus (15 analysts)
hold
Avg. price target
$22.75-7.89%
- Strong buy 2
- Buy 3
- Hold 9
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 4, 2026
- EPS actual vs est.
- $-0.38 vs $-0.39
- Surprise
- +2.56%
PRCT news
All PRCT news- PROCEPT BioRobotics® to Participate in the Piper Sandler 38th Annual Healthcare Conference on December 2, 2026GlobeNewswire
- PROCEPT BioRobotics® to Report Third Quarter 2026 Financial Results on November 4th, 2026GlobeNewswire
- Monday's ETF Movers: IHI, REMXNasdaqPRCT, CBLL, ALM, ELVR
- Barclays Initiates Coverage of PROCEPT BioRobotics with Overweight RatingNasdaqPRCT, BCS
- Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch.NasdaqPTGX, JNJ, LAB, XNCR
PROCEPT BioRobotics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| KMTSKestra Medical Technologies Ltd. | 25.10 | -5.75% | $1.50B | vs PRCT |
| NVCRNovoCure Limited | 10.71 | +0.19% | $1.25B | vs PRCT |
| INSPInspire Medical Systems Inc. | 55.10 | -2.10% | $1.60B | vs PRCT |
| TNDMTandem Diabetes Care Inc. | 17.46 | +3.93% | $1.22B | vs PRCT |
| XRAYDENTSPLY SIRONA Inc. | 8.29 | -2.36% | $1.65B | vs PRCT |
| LMATLeMaitre Vascular Inc. | 73.61 | -1.67% | $1.68B | vs PRCT |
| DRTSAlpha Tau Medical Ltd. | 11.76 | +3.93% | $1.09B | vs PRCT |
| SIBNSI-BONE Inc. | 23.73 | -0.08% | $1.07B | vs PRCT |
Indexes, lists and sector
PROCEPT BioRobotics stock FAQ
What is PROCEPT BioRobotics's stock price today?
PRCT last traded at $24.70 as of Nov 20, 4:00 PM EST, down 4.08% on the day. Prices are delayed at least 15 minutes.
Who is PROCEPT BioRobotics's CEO?
Mr. Larry L. Wood is the chief executive officer of PROCEPT BioRobotics Corporation, which has about 888 employees.
What is the PRCT 52-week high?
The 52-week high for PRCT is $38.11 and the 52-week low is $16.67. The stock is currently 35.2% below its high.